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Articles
Long-term clinical and cost-eﬀ ectiveness of psychological 
intervention for family carers of people with dementia: 
a single-blind, randomised, controlled trial
Gill Livingston, Julie Barber, Penny Rapaport, Martin Knapp, Mark Griﬃ  n, Derek King, Renee Romeo, Debbie Livingston, Cath Mummery, 
Zuzana Walker, Juanita Hoe, Claudia Cooper
Summary
Background Two-thirds of people with dementia live at home supported mainly by family carers. These carers 
frequently develop clinical depression or anxiety, which predicts care breakdown. We aimed to assess the clinical 
eﬀ ectiveness (long-term reduction of depression and anxiety symptoms in family carers) and cost-eﬀ ectiveness of a 
psychological intervention called START (STrAtegies for RelaTives).
Methods We did a randomised, parallel-group trial with masked outcome assessments in three UK mental-health 
services and one neurological-outpatient dementia service. We included self-identiﬁ ed family carers of people with 
dementia who had been referred in the previous year and gave support at least once per week to the person with 
dementia. We randomly assigned these carers, via an online computer-generated randomisation system from an 
independent clinical trials unit, to either START, an 8-session, manual-based coping intervention delivered by 
supervised psychology graduates, or treatment as usual (TAU). The primary long-term outcomes were aﬀ ective 
symptoms (Hospital Anxiety and Depression Scale total score [HADS-T]) 2 years after randomisation and cost-
eﬀ ectiveness (health and social care perspectives) over 24 months. Analysis was by intention to treat, excluding 
carers with data missing at both 12 and 24 months. This trial is registered ISCTRN70017938.
Findings From November 4, 2009, to June 8, 2011, we recruited 260 carers. 173 carers were randomly assigned to 
START and 87 to TAU. Of these 260 participants, 209 (80%) were included in the clinical eﬃ  cacy analysis 
(140 START, 69 TAU). At 24 months, compared with TAU the START group was signiﬁ cantly better for HADS-T 
(mean diﬀ erence –2·58 points, 95% CI –4·26 to –0·90; p=0·003). The intervention is cost eﬀ ective for both carers 
and patients (67% probability of cost-eﬀ ectiveness at the £20 000 per QALY willingness-to-pay threshold, and 70% 
at the £30 000 threshold).
Interpretation START is clinically eﬀ ective, improving carer mood and anxiety levels for 2 years. Carers in the 
control TAU group were seven times more likely to have clinically signiﬁ cant depression than those receiving 
START. START is cost eﬀ ective with respect to carer and patient outcomes, and National Institute for Health and 
Care Excellence (NICE) thresholds. The number of people with dementia is rapidly growing, and policy 
frameworks assume that their families will remain the frontline providers of (unpaid) support. This cost-neutral 
intervention, which substantially improves family-carers’ mental health and quality of life, should therefore be 
widely available.
Funding National Institute for Health Research Health Technology Assessment programme 08/14/06.
Copyright © Livingston et al. Open Access article distributed under the terms of CC-BY-NC-ND.
Introduction
Two-thirds of people with dementia live at home, with 
their family providing most of their care.1 About 40% of 
family carers of people with dementia have clinical 
depression or anxiety; others have substantial psycho-
logical symptoms.2,3 Carer psychological morbidity 
predicts care breakdown and care home admission.4
The STrAtegies for RelaTives (START) psychological 
intervention for family carers has been the ﬁ rst to show 
both clinical eﬀ ectiveness (reduced anxiety and depressive 
symptoms, reduced depression caseness, and improved 
quality of life) and cost-eﬀ ectiveness for family carers of 
people with dementia.5,6 These were short-term results 
(8 months), and for how long these eﬀ ects are sustained 
is unclear. Previous studies of family carers suggest that 
eﬀ ects persist for 7–11 months.7 A multicomponent 
intervention showed no eﬀ ect at 4 months, but the eﬀ ect 
at 1 year was sustained for another 2 years.8
We therefore tested START’s long-term primary 
hypothesis that this intervention would show clinical 
and cost-eﬀ ectiveness for family carers’ aﬀ ective 
psychological symptoms 2 years after randomisation. 
We also examined clinical and cost-eﬀ ectiveness for 
people with dementia. We prespeciﬁ ed a primary short-
term outcome at 8 months and a primary long-term 
outcome at 24 months.
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Methods
Study design and participants
START is a parallel-group, superiority, single-blind, 
randomised controlled trial, which recruited participants 
2:1 to START intervention or treatment as usual (TAU) to 
allow for therapist clustering, and was undertaken in the 
UK at four sites. The methods have been reported in 
detail elsewhere.5,6
Eligible participants were self-identiﬁ ed family carers 
providing support at least once per week to people with a 
clinical diagnosis of dementia, living in their own homes 
and referred in the previous year. Carers who were unable 
to give informed consent to the trial, or who were already 
in a trial of carer support or who lived more than 1·5 h 
from the researchers’ base were excluded. We recruited 
participants through three mental health trusts and a 
tertiary neurology clinic. Ethics approval was obtained, and 
participants gave written, informed consent.
Randomisation and masking
Randomisation was stratiﬁ ed by centre with random 
permuted blocks of diﬀ erent sizes via an online 
computer-generated randomisation system from an 
independent clinical trials unit. Assessors were unaware 
of the randomisation status, but the trial participants 
knew their allocation.
Procedures
We developed the 8-session START manual-based, 
individual coping intervention for dementia family 
carers from the US Coping with Caregiving 
intervention.9 We trained and supervised non-clinically 
trained psychology graduates to deliver START, and 
monitored intervention ﬁ delity by devising checklists 
that rated the most important components of every 
session. Therapists (the psychology graduates) recorded 
one therapy session per participant selected randomly 
by the trial manager. This session was completed by a 
therapist in the same team who was not associated with 
that participant’s intervention. An overall ﬁ delity score 
for every session was then given by the assessor, from 1 
(not at all) to 5 (very focused).
The full START intervention manual is in the 
appendix and can be used after training. START is also 
summarised in panel 1. Therapists were trained and 
supervised as a group with additional time available for 
individual support. The graduate therapists were 
encouraged to be empathetic, adhere to the intervention, 
and to work with carers to ﬁ nd answers rather than give 
solutions or advice. Together they identiﬁ ed individual 
diﬃ  culties and implemented strategies including 
relaxation, behavioural management, communication 
strategies, identiﬁ cation and changing of unhelpful 
thoughts, positive reframing, accessing of emotional 
support, future planning, and increasing occurrence of 
pleasant events.
Every session ﬁ nished with a relaxation session using a 
tailored CD. We asked carers to practise the strategies 
from the manual and listen to the relaxation CDs 
between sessions. The ﬁ nal session included the 
development of a maintenance plan of useful strategies. 
Sessions were usually in participants’ homes, unless they 
preferred the team’s oﬃ  ce.
TAU within the health-care trusts connected with the 
trial was based on National Institute for Health and 
Care Excellence (NICE) guidelines,10 with services based 
around the person with dementia. TAU is medical, 
psychological, and social, and is supposed to consist of 
assessment, diagnosis and information-giving, risk 
assessment and management (eg, assessments of risk 
of ﬁ re, driving standards, adequate nutrition and self-
care, vulnerability, and management of money), drug 
treatment, cognitive-stimulation therapy, practical 
support, treatment of neuropsychiatric and cognitive 
symptoms, assessment of capacity to make long-term 
decisions and help given to make them, and carer 
support. We judged that the health trusts in our study 
had high TAU standards.
Outcomes
After the trial started, with funding body approval 
(while the database was locked), we agreed that the 
primary outcome should be Hospital Anxiety and 
Depression  Scale total score (HADS-T) because this 
has better sensitivity and positive predictive value than 
the anxiety or depression score for identifying 
depression.11 The primary outcomes were HADS-T 
2 years after randomisation and cost-eﬀ ectiveness 
(health and social care perspectives) over 24 months. 
The same primary outcomes were also assessed after 
8 months for the short-term eﬀ ects.
We obtained carer and patient sociodemographic 
details at baseline, and the following data at baseline, 4, 
8, 12, and 24 months after randomisation:
Panel 1: The START Manual: STrAtegies for RelaTives
Session 1: Stress and wellbeing
Session 2: Reasons for behaviour
Session 3: Making a behaviour plan
Session 4: Behaviour strategies and unhelpful thoughts
Session 5: Communication styles
Session 6: Planning for the future
Session 7: Introduction to pleasant events and your mood
Session 8: Using your skills in the future
Therapists worked on a one-to-one basis with carers to 
identify individual diﬃ  culties and implement strategies.
Carers kept their own manual and ﬁ lled it in. Every session 
ﬁ nished with a relaxation session. Carers were asked to 
practice the strategies and relaxation between sessions.
See Online for appendix
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For carers: Hospital Anxiety and Depression Scale 
(HADS),11,12 a validated, self-complete scale11 sum-
marised as HADS-D (depression) and HADS-A 
(anxiety) with scores from 0 to 21, and a total HADS 
score (HADS-T) from 0 to 42 (high scores are suggestive 
of more symptoms). HADS-D and HADS-A are also 
validated as scores for caseness, classiﬁ ed as a case or 
non-case, with a cutoﬀ  point of 8–9;11 Zarit Burden 
Interview13 to adjust for baseline carer burden because 
carers with a high burden might be more stressed; 
Brief COPE,14 a self-complete, coping strategies 
measure, validated in family dementia carers,15 with 
subscales for diﬃ  culty-focused, emotion-focused, and 
dysfunctional coping; Health Status Questionnaire 
(HSQ)16,17 that measures mental-health domain 
measures of quality of life; European quality of life ﬁ ve 
dimensions questionnaire (EQ-5D)18 that measures 
health status, generating a usefulness score; Client 
Service Receipt Inventory (CSRI)19 that measures carer 
health and social care service use over 4 months 
retrospectively; and the Modiﬁ ed Conﬂ ict Tactics Scale 
(MCTS) that measures potentially abusive behaviour by 
carers towards care recipients. Ten behaviours, ranging 
from shouting to slapping, over the previous 3 months 
are rated from never (0) to all the time (4). A score of at 
least 2 for any item is classiﬁ ed as abusive.20
Carer’s information about the patient: Clinical 
Dementia Rating (CDR) of dementia severity from very 
mild (0·5) to severe (3);21 Neuropsychiatric Inventory 
(NPI)22 to adjust for baseline NPI. High patient neuro-
psychiatric symptoms increase carer psychological 
morbidity; Quality of life-Alzheimer’s Disease23 that 
measures the quality of life for a patient with Alzheimer’s; 
and a CSRI that retrospectively measures patient health 
and social care service use over 4 months.
We did not obtain data for adverse events, because we 
judged that such events, in terms of carers being unwell, 
would not be due to the therapy. We did obtain adverse 
outcomes in terms of costs, which are reported later in 
the Article.
Statistical analysis
This study was originally powered for a primary outcome 
of HADS anxiety score5 needing a sample size of 90 in 
the control TAU group and 168 in START (participant 
allocation was unequal to allow for therapist clustering in 
START). When the primary outcome was changed to 
HADS-T, the sample then available (87 TAU, 173 START) 
was suﬃ  cient to detect a mean diﬀ erence in HADS-T of 
at least 2·4 points (with 80% power, 5% signiﬁ cance) 
assuming an SD of 7·4 (as for pilot data), allowing for 
analysis of covariance (assumed correlation 0·5) and two 
repeated follow-up measurements (assumed correlation 
0·7). A drop-out of 10% was assumed, and a design eﬀ ect 
of 1·4 was applied for the START group (with an 
intracluster correlation coeﬃ  cient of 0·03)24 and an 
average cluster size of 15 carers per therapist).
In the primary analysis, we used regression methods to 
estimate group diﬀ erences in long-term follow up (12 
and 24 months) for HADS-T, treatment costs for carers, 
and quality-adjusted life-years (QALYs) calculated from 
European quality of life-5D measures with societal 
weights.25 Random-eﬀ ects models accounted for therapist 
clustering in the START group and measurements were 
repeated at 12 and 24 months. We adjusted results for 
baseline total score, centre (by which randomisation was 
stratiﬁ ed), and factors known to have an eﬀ ect on 
aﬀ ective symptoms (patient age, sex, and NPI, and carer 
burden). For cost-eﬀ ectiveness analyses, we adjusted for 
the same characteristics, plus prerandomisation costs. 
Non-parametric bootstrapping was used to estimate 
95% CIs for mean costs because of skewed data. All 
analyses were by intention-to-treat but excluded carers 
with data missing at both 12 and 24 months. Because 
QALY estimation needs data at every timepoint, we 
included only complete cases for this analysis.
Sensitivity analyses for both clinical and economic 
outcomes were tested for robustness, with adjustments 
made ﬁ rst for imbalances in baseline characteristics and 
second for predictors of missing outcomes. The eﬀ ect of 
missing data was also addressed, for clinical outcomes, 
with a multiple-imputation method. By inclusion of 
interaction terms, we examined possible diﬀ erential 
eﬀ ects of treatment at 12 and 24 months and ﬁ tted models 
incorporating all repeated measurements, to explore 
diﬀ erential treatment eﬀ ects over both short-term (up to 
8 months) and long-term (up to 24 months) periods.
Similar approaches were taken for cost-eﬀ ectiveness 
and analysis of secondary outcomes. Random eﬀ ects 
logistic regression was used for binary outcomes. 
START’s eﬀ ect on time until care home admission was 
examined with parametric, shared, frailty models, 
allowing for clustering in the START group and 
adjustment for baseline factors. Models had gamma 
distribution for shared frailty and Weibull distribution 
for time until care home admission.
Unit costs were set at 2009–10 prices.26,27 Costs and 
outcomes in the second year were discounted at 3·5%.28 
START intervention cost was calculated from therapist 
time spent in training, supervision, and intervention 
delivery. The relaxation CDs were costed at market rates 
for copying and delivery.6 Costs were calculated separately 
for carers’ and patients’ service use, from a health and 
social care perspective. Costs for months 13 to 21 were 
estimated by interpolation from data obtained at 12 and 
24 months to generate costs for the full period.
We calculated incremental cost-eﬀ ectiveness ratios 
(diﬀ erence in cost between START and TAU divided by 
diﬀ erence in outcome) for carer plus patient costs and, in 
turn, two carer outcomes (HADS-T, quality-adjusted life-
years) and one patient outcome (quality of life-
Alzheimer’s Disease) over 24 months. We repeated these 
analyses for carer-only costs. In view of the uncertainty in 
estimation of costs and outcomes, we plotted cost-
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eﬀ ectiveness acceptability curves using a net-beneﬁ t 
approach across a range of willingness-to-pay values.
We used the STATA version 11 computer program to do 
the statistical analyses for the clinical outcomes, and 
STATA version 12 for the cost-eﬀ ectiveness analyses. 
This trial is registered ISCTRN70017938.
Role of the funding source
The funder of the study had no role in study design, data 
collection, analysis, data interpretation, manuscript writing, 
or decision to submit for publication. GL, CC, JB, MK, RR, 
DK, DL, and MG had access to all the data. All authors had 
ﬁ nal responsibility for the decision to submit for publication.
166 received at least one session of START
130 received at least ﬁve sessions
13 lost to 4 month follow up
1 carer died
10 withdrew
3 did not like the intervention
2 too busy
1 disliked discussing the care 
recipient
2 gave no reason
1 was upset at the study
1 not contactable
1 had inconsistent data
1 was imprisoned 
8 lost to 8 month follow-up
8 withdrew
2 too busy
1 unwell
1 care recipient unwell
2 thought study had not helped
2 not contactable
8 lost to 12 month follow-up
1 carer died
6 withdrew
1 unwell
3 not contactable
1 refused follow-up
1 gave no reason
1 was prevented because they 
developed dementia
12 lost to 24 month follow-up
3 carers died
9 withdrew
1 went abroad
1 care recipient died
1 in care home
1 unwell
1 too busy
4 gave no reason
472 carers assessed for eligibility
260 enrolled and randomised
212 excluded
22 did not meet inclusion criteria
181 refused to participate
9 could not be contacted
173 allocated to START
160 completed 4 month 
follow-up session
77 completed 4 month 
follow-up session
152 completed 8 month 
follow-up session
75 completed 8 month 
follow-up session
144 completed 12 month 
follow-up session
70 completed 12 month 
follow-up session
132 completed 24 month 
follow-up session
64 completed 24 month 
follow-up session
140 analysed for primary outcome 69 analysed for primary outcome 
87 allocated to TAU 87 received TAU
10 lost to 4 month follow-up
1 died
9 withdrew
4 wanted treatment but not
allocated to it
1 too busy
3 not contactable
1 disliked discussing the care 
recipient
2 lost to 8 month follow-up
2 withdrew
1 care recipient died
1 family wanted to withdraw
5 lost to 12 month follow-up
5 withdrew
1 unwell
1 care recipient died
3 gave no reason
6 lost to 24 month follow-up
6 withdrew
1 did not want to continue
2 too busy
3 no reason
Figure 1: Trial proﬁ le
To be included in the primary long-term analysis, the individual should have had at least one Hospital Anxiety and Depression Scale (HADS) score at 12 or 24 months. 
START=STrAtegies for RelaTives (intervention). TAU=treatment as usual (control). People were included in the ﬁ nal analyses if they gave data about the HADS at 12 
or 24 months. 
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Results
472 carers were referred to us for potential inclusion in 
our trial. Of these, 181 (38%) refused to take part, 22 (5%) 
did not meet inclusion criteria, and nine (2%) were not 
contactable. Those who consented were slightly more 
likely to be married to the patient than those who did not 
consent.5 Therefore we randomly assigned 260 (55%) of 
472 of the carers referred between Nov 4, 2009, to June 8, 
2011 to one of the trial groups (ﬁ gure 1). 173 (67%) 
participants were assigned to START intervention and 
87 (33%) to TAU. Randomisation generally achieved 
good balance in terms of sociodemographic and clinical 
characteristics (table 1).
130 (75%) carers in the intervention group attended at 
least ﬁ ve therapy sessions, eight (5%) withdrew before 
any therapy sessions. Each of ten therapists (seven 
women) delivered the intervention to between 11 and 
32 carers, with a mean ﬁ delity score of 4·7/5 (SD 0·66). 
Primary clinical analyses included 209 (80·4%) 
participants with HADS-T data at 12 or 24 months. 
Table 2 shows the primary outcomes. Analysis of 
HADS-T at 24 months, adjusting for centre, baseline 
score, and factors related to outcome (carer age and sex, 
NPI, Zarit) showed a mean diﬀ erence of –2·58 points 
(95% CI –4·26 to –0·90; p=0·003) in favour of START.
In the model not including outcome-related factors, 
mean HADS-T decrease was –1·84 (95% CI –3·50 to 
–0·17; p=0·03). Sensitivity analyses adjusting for relevant 
predictors of missing HADS-T scores (coresidence with 
carer and a high COPE dysfunction score) showed a mean 
diﬀ erence of –2·69 (95% CI –4·39 to –0·98, p=0·002, 
n=200), and adjustment for baseline imbalances (carer 
work, carer education, patient education, relationship with 
carer, and living with carer) showed a mean diﬀ erence of 
–2·37 (–4·11 to –0·63, p=0·008). Results were also similar 
after multiple imputation (–2·28; –3·94 to –0·63, n=260).
Models including interaction with time showed no 
evidence of diﬀ erential eﬀ ects at 12 or 24 months 
(p=0·76). Short (up to 8 months) and long-term eﬀ ects 
(12 to 24 months) showed no diﬀ erences (p=0·92).
Signiﬁ cantly fewer cases of HADS-depression occurred 
in START compared with TAU (odds ratio [OR] 0·14, 
95% CI 0·04–0·53). The diﬀ erence in HADS-anxiety 
caseness was not signiﬁ cant (OR 0·57, 0·26–1·24).
Adjusted models for HADS-anxiety and HADS-
depression continuous scores showed signiﬁ cant 
beneﬁ cial intervention eﬀ ects over 24 months with 
START, with mean decreases of –1·16 (95% CI –2·15 to 
–0·18, n=200) and –1·45 (–2·32 to –0·57), respectively. 
Models showed no evidence of diﬀ erential intervention 
eﬀ ects with time for HADS-anxiety or HADS-depression 
(p=0·99 and p=0·86, respectively).
START improved carer Health Status Questionnaire-
Mental Health scale compared with TAU (mean 
diﬀ erence 7·47 [95% CI 2·87–12·08], n=183). Patient 
quality-of-life-Alzheimer’s Disease measurements did 
not diﬀ er between groups. Models including an 
interaction with time showed no evidence of diﬀ erential 
eﬀ ect for quality-of-life-Alzheimer’s Disease measure-
ments or Health Status Questionnaire-Mental Health 
scale (p=0·24 and p=0·14, respectively).
17 (20%) of 84 patients whose carers were receiving 
TAU and 32 (18%) of 171 whose carers were receiving 
START moved to a care home within the 24 month trial 
period. In regression models, no signiﬁ cant diﬀ erence in 
Carer Patient
TAU (n=87) START (n=172) TAU (n=87) START (n=173)
Age (years) 56·1 (12·3) 62·0 (14·6) 78·0 (9·9) 79·9 (8·3)
Women 62 (71%) 116 (67%) 50 (58%) 102 (59%)
Ethnicity
White UK 65 (75%) 131 (76%) 61 (70%) 126 (73%)
White other 5 (6%) 10 (6%) 6 (7%) 14 (8%)
Black and minority 17 (20%) 31 (18%) 20 (23%) 33 (19%)
Not currently married 25 (29%) 61 (35%) 47 (54%) 92 (53%)
Education
No qualiﬁ cations 18 (21%) 45 (26%) 44 (51%) 73 (45%)
School level 33 (38%) 51 (30%) 16 (19%) 28 (17%)
Further education 36 (41%) 77 (45%) 26 (30%) 63 (38%)
Work
Full time 28 (32%) 36 (20%) NA NA
Part time 20 (23%) 27 (16%) NA NA
Retired 23 (26%) 80 (46%) NA NA
Not working 16 (18%) 30 (17%) NA NA
Living with carer NA NA 50 (58%) 113 (65%)
Relationship to patient
Partner 31 (36%) 78 (45%) NA NA
Child 42 (48%) 71 (41%) NA NA
Other 14 (16%) 24 (14%) NA NA
NPI Total NA NA 26·6
(20·1; n=86)
24·0
(19·0; n=171)
CDR overall score NA NA 1·3
(0·6; n=87)
1·2
(0·6; n=171)
Zarit 38·1
(17·0; n=84)
35·3
(18·4; n=165)
NA NA
HADS-T score 14·8 (7·4) 13·5 (7·3) NA NA
HADS-A score 9·3 (4·3) 8·1 (4·4) NA NA
HADS-D 5·5 (3·9) 5·4 (3·8) NA NA
EQ5D 0·79 (0·18) 0·74 (0·24) NA NA
QOL-AD NA NA 29·9 (6·9) 30·2 (6·9)
HSQ mental health 58·2 (21·7) 58·3 (22·4) NA NA
HADS Anxiety Case (score ≥9 ) 48 (55%) 85 (49%) NA NA
HADS Depression Case (score ≥9) 17 (20%) 36 (21%) NA NA
MCTS (at least one item score ≥2) 38 (44%) 82 (48%) NA NA
Cost (£, during a 4 month period 
prebaseline)
315 218 3205 2446
Data are n (%) or mean (SD). If some participants did not complete the measure, the changed n is given.NA=not 
applicable. TAU=treatment as usual. START=STrAtegies for RelaTives. HADS=Hospital Anxiety and Depression Scale. 
CDR =Clinical Dementia Scale. MCTS=Modiﬁ ed Conﬂ ict Tactics Scale. Zarit=Zarit Burden Interview. EQ5D=European 
quality of life ﬁ ve dimensions questionnaire. NPI=Neuropsychiatric Inventory. QOL-AD=Quality of Life-Alzheimer’s 
Disease. HSQ=Health Status Questionnaire
 Table 1: Baseline characteristics of the intention-to-treat population
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time until care home admission by randomised group 
was noted (hazard ratio [HR] 0.83, 95% CI 0·44–1·56, 
p=0·56; n=242) adjusted for centre, carer age, carer sex, 
and baseline NPI and Zarit score. Sensitivity analyses 
adjusted for baseline imbalances (carer work, carer 
education, patient education, relationship with carer, and 
living with carer) gave HR 0·62 (0·31–1·23, p=0·17; 
n=232). The appendix shows a Kaplan-Meier plot for 
times to care home admission.
196 (75%) carers had 24 month follow-up service use 
data (64 TAU, 132 START). Service use patterns are in the 
appendix. Health-care costs for carers in the START 
group were not higher than those in the TAU group, 
suggesting that START did not cause substantial adverse 
health events. 
Mean therapy cost was £232 per carer. When adjusted 
for baseline characteristics, carer-service costs were 
slightly higher in the START group than in the TAU 
group, but not signiﬁ cantly diﬀ erent between groups 
from 1 to 24 months (£170; 95% CI –132 to 472), and 
patient-service costs were lower in START than in TAU, 
but were also not signiﬁ cantly diﬀ erent between the 
groups over the same period (–£1368; 95% CI –5027 to 
2291; table 3).
Cost-eﬀ ectiveness analyses included carer-only costs 
and carer-and-patient costs combined. Sample sizes in 
cost-eﬀ ectiveness analyses are smaller because of missing 
values.
In the main analyses with combined costs (table 4), 
START dominates TAU when looking at carer outcomes 
(HADS-T and quality-adjusted life-years), because 
outcomes are better and costs not signiﬁ cantly diﬀ erent. 
For the second primary outcome of cost-eﬀ ectiveness 
(with quality-adjusted life-years as an outcome [ﬁ gure 2]), 
START is cost eﬀ ective with respect to NICE thresholds 
(67% probability of cost-eﬀ ectiveness at £20 000 per 
quality-adjusted lifeyear willingness-to-pay threshold; 
70% at £30 000 threshold).28
For patient quality of life-Alzheimer’s Disease 
measures, neither cost nor outcome was signiﬁ cantly 
diﬀ erent between the groups. In view of uncertainty in 
the analyses, cost-eﬀ ectiveness acceptability curves were 
plotted. For quality of life-Alzheimer’s Disease measures, 
the curve suggests a high probability of cost-eﬀ ectiveness 
(ﬁ gure 2) at all willingness-to-pay values. For HADS-T, 
the curve again shows a high probability of cost-
eﬀ ectiveness for the intervention (appendix) across all 
willingness-to-pay values, although there is no externally 
recommended threshold.
When looking only at carer-only costs, the pattern of 
cost-eﬀ ectiveness is little changed (table 4). Cost per QALY 
is now £12 400, again less than the NICE threshold. From 
a health and social care perspective, cost-eﬀ ectiveness 
analyses using combined costs are more relevant.
To assess the robustness of these ﬁ ndings, we adjusted 
the results for relevant predictors of missing data, which 
gave similar results–the intervention having a 67% 
likelihood of cost-eﬀ ectiveness at the NICE £20 000 per 
quality-adjusted life-year threshold (75% at £30 000 
threshold). For the second sensitivity analysis with 
adjustments for baseline characteristics imbalances, 
mean incremental cost-eﬀ ectiveness ratios (ICERs) 
change (table 4), as does the pattern of probability of cost-
eﬀ ectiveness across the willingness-to-pay range (see 
TAU at 
12 months 
(n=67)
TAU at 
24 months 
(n=64)
START at 
12 months 
(n=138)
START at 
24 months 
(n=132)
Diﬀ erences adjusted for 
baseline and centre 
(n=209)
Diﬀ erences in scores at 
24 months adjusted for 
baseline, centre, carers’ 
age, sex, NPI and Zarit 
(n=200)
HADS Total 14·6 (8·9) 15·5 (9·5) 12·5 (7·9) 13·6 (8·3) –1·84* (–3·50 to –0·17) –2·58* (–4·26 to –0·90)
HADS Depression Case 
(score ≥9)
18 (27%) 19 (30%) 24 (17%) 30 (23%) 0·22† (0·05–0·96) 0·14† (0·04–0·53);
(n=192)
HADS Anxiety Case 
(score ≥9)
33 (49%) 32 (50%) 54 (39%) 57 (43%) 0·53† (0·24–1·16) 0·57† (0·26–1·24)
HADS Anxiety 8·8 (5·1) 9·2 (5·3) 7·5 (4·4) 8·1 (4·9) –0·75* (–1·75 to 0·25) –1·16* (–2·15 to –0·18)
HADS Depression 5·9 (4·3) 6·3 (4·9) 5·0 (4·2) 5·5 (4·2) –1·14 (–2·00 to –0·28) –1·45* (–2·32 to –0·57)
HSQ–Mental Health 56·2 (22·5);
(n=61)
55·0 (21·3);
(n=55)
61·9 (20·6);
(n=121)
60·2 (19·8);
(n=113)
7·16* (2·72–11·60);
(n=189)
7·47* (2·87–12·08);
(n=183)
QOL-AD 30·0 (6·4);
(n=53)
29·4 (7·0);
(n=49)
30·5 (6·7);
(n=114)
29·9 (6·7);
(n=95)
0·16* (–1·30 to 1·63);
(n=174)
0·17* (–1.37 to 1·70);
(n=168)
MCTS (at least one item 
with a score ≥2)
21 (38%);
(n=55)
11 (23%);
(n=47)
41 (36%);
(n=114)
28 (30%);
(n=95)
0·96† (0·42–2·19);
(n=176)
0·83† (0·36–1·93);
(n=171)
Data are mean (SD), n (%), or diﬀ erence (95% CI), unless otherwise indicated. Treatment eﬀ ect estimates (diﬀ erences and odds ratios) are from models taking into account 
repeated measurements, therapist clustering in the intervention arm and which are adjusted for ba seline characteristics. TAU=treatment as usual. START=STrAtegies for 
RelaTives. HADS=Hospital Anxiety and Depression Scale. Zarit=Zarit Burden Interview. NPI=Neuropsychiatric Inventory. MCTS=Modiﬁ ed Conﬂ ict Tactics Scale. 
QOL-AD=Quality of Life-Alzheimer’s Disease. HSQ=Health Status Questionnaire. One person with dementia was noted to have two carers (spouse and daughter) in the 
intervention group. This person was represented only once in the analysis of patient outcomes. Therapist intracluster correlation at 12 months was 0·0 (95% CI 0–0·07) and at 
24 months was 0·0 (0–0·07). *Data are treatment-eﬀ ect diﬀ erences between START and TAU; 95% CI), †data are odds ratios (95% CI).
Table 2: Primary and secondary outcomes at 12 and 24 months
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appendix). The change in the ICER for the quality-adjusted 
life-year outcome is exaggerated by the very small between-
group diﬀ erence, but the eﬀ ect on the cost-eﬀ ectiveness 
acceptability curve is slight—eg, at £20 000 willingness-to-
pay threshold, START has a 50% likelihood of being cost 
eﬀ ective. With respect to HADS-T, START has more than 
a 50% likelihood of cost-eﬀ ectiveness at all willingness-to-
pay values. With respect to patient quality-of-life measures 
for Alzheimer’s Disease, the case for START’s cost-
eﬀ ectiveness is weaker in the sensitivity analysis; when 
Incremental diﬀ erence (START minus TAU) and cost-
eﬀ ectiveness ratio over 1–24 months (main analyses)
Incremental diﬀ erence (START minus TAU) and cost-
eﬀ ectiveness ratio over 1–24 months (sensitivity analysis)*
With carer-only costs With carer-plus-patient costs With carer-only costs With carer-plus-patient costs
Carer HADS-T n=168 n=163 n=161 n=157
Incremental costs (mean £ [95% CI]) 287 (–207 to 782) –1324 (–9987 to 7339) 262 (–226 to 750) –118 (–8873 to 8636)
Incremental HADS-T change: mean (95% CI) –1·60 (–3·69 to 0·49) –1·49 (–3·47 to –0·50) –1·47 (–3·69 to 0·74) –1·36 (–365 to –0·92)
Incremental cost-eﬀ ectiveness ratio (£ per 1-point 
diﬀ erence for HADS-T)†
179 –889 178 –87
Carer QALY n=147 n=145 n=141 n=140
Incremental costs (mean £ [95% CI]) 372 (–189 to 933) –1471 (–10 909 to 7968) 321 (–286 to 927) 698 (–9459 to 10 855)
Incremental QALY gain: mean (95% CI) 0·03 (0·00 to 0·06) 0·03 (0·00 to 0·07) 0·03 (0·00 to 0·06) 0·03 (0·00 to 0·06)
Incremental cost-eﬀ ectiveness ratio (£ per QALY gain) 12 400 –49033 10 700 23 267
Patient QOL-AD n=134 n=131 n=129 n=127
Incremental costs (mean £ [95% CI]) 266 (–328 to 859) –3412 (–12 483 to 5659) 233 (–398 to 864) 1791 (–7595 to 11 176)
Incremental QOL-AD change: mean (95% CI) 1·09 (–0·75 to 2·92) 0·55 (–1.38 to 2·48) 0·88 (–1·14 to 2·90) 0·54 (–1·53 to 2·61)
Incremental cost-eﬀ ectiveness ratio (£ per 1-point 
diﬀ erence for QOL-AD)
244 –6204 265 3317
Data are given by outcome. HADS-T=Hospital Anxiety and Depression Scale-Total score. QALY=quality-adjusted life-year. QOL-AD=Quality of Life-Alzheimer’s Disease. Sample sizes were based on complete data 
for each outcome and combined cost measures. *Additional covariates were added to the model to adjust for imbalances in baseline characteristics.  †Sign reversed in line with convention for cost-eﬀ ectiveness 
ratios. 
 Table 4: Carer-only costs and carer-plus-patient costs combined
TAU* START* START versus TAU from 1 to 24 months
1–12 months 13–24 months 1–12 months 13–24 months Diﬀ erence adjusted for score at 
baseline and centre
Diﬀ erence adjusted for score at 
baseline, centre, and baseline 
variables†
Costs for carers (£, 2009–10)
Hospital 370 (963) 291 (679) 275 (436) 435 (1530) 51 (–182 to 284) (n=208) 49 (–190 to 287) (n=199)
Community health 349 (554) 313 (623) 324 (458) 330 (425) –1 (–116 to 113) (n=208) –28 (–147 to 90) (n=199)
Community social care 11 (29) 0 (0) 57 (538) 28 (209) 36 (–54 to 126) (n=208) 15 (–80 to 110) (n=199)
Intervention 0 (0) 0 (0) 232 (98) 0 (0) 116 (96 to 136) (n=260) 115 (94 to 136) (n=247)
Total 730 (1155) 598 (907) 912 (1012) 783 (1626) 240 (–61 to 542) (n=208) 170 (–132 to 472) (n=199)
Costs for patients (£, 2009–10)
Hospital 3660 (6411) 3909 (6460) 2375 (5582) 3642 (7826) –683 (–2109 to 744) (n=206) –735 (–2210 to 740) (n=197)
Community health 1002 (1895) 924 (1885) 64 (968) 72 (1236) –205 (–591 to 181) (n=206) –220 (–622 to 182) (n=197)
Community social care 3054 (5226) 4388 (15 338) 4017 (12 024) 4875 (17 050) 1352 (–1900 to 4603) (n=206) 1144 (–2207 to 4496) (n=197)
Care home 1755 (7176) 4682 (11 610) 1000 (4762) 2922 (8071) –1281 (–3277 to 715) (n=213) –1536 (–3535 to 463) (n=204)
Total 9577 (13 524) 13 904 (19 051) 7922 (14 410) 12 358 (19 976) –649 (–4263 to 2965 (n=206) -1368 (–5027 to 2291) (n=197)
Outcomes used in economic evaluation
Carer: EQ5D 0·81 (0·19) 0·80 (0·19) 0·79 (0·23) 0·77 (0·26) 0·04 (–0·04 to 0·12) (n=190) 0·05 (–0·03 to 0·13) (n=184)
Carer: QALY 0·79 (0·15) 0·75 (0·16) 0·80 (0·18) 0·73 (0·21) 0·02 (–0·02 to 0·06) (n=179) 0·03 (–0·01 to 0·07) (n=174)
Carer: HADS-T 14·6 (8·9) 14·4 (8·9) 12·5 (7·9) 12·7 (7·7) –1·75 (–3·31 to –0·19) (n=209) –2·47 (–4·03 to-0·91) (n=200)
Patient: QOL-AD 30·0 (6·4) 27·4 (6·5) 30·5 (6·7) 27·9 (6·3) 0·28 (–1·09 to 1·66) (n=174) 0·26 (–1·16 to 1·68) (n=168)
Data are mean (SD), n (%), or diﬀ erence (95% CI) (sample size). TAU=treatment as usual.START=STrAtegies for RelaTives. EQ5D=European quality of life ﬁ ve dimensions questionnaire. QALY=quality-adjusted life-
year. HADS-T=Hospital Anxiety and Depression Scale-Total score. QOL-AD=Quality of Life-Alzheimer’s Disease. *Not adjusted for any baseline scores or centre.†For carers, diﬀ erences adjusted for baseline score, 
centre, age, sex, Neuropsychiatric Inventory, and the Zarit Burden Interview. Outcomes also adjusted for baseline total carer cost. For patients, diﬀ erences adjusted for baseline score, centre, patient’s age, sex, NPI, 
and carer’s Zarit. Outcomes are also adjusted for baseline total patient costs.
Table 3: Carer and patient costs and outcomes
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including carer-only costs, the cost per quality-adjusted 
life-year becomes £23 267 (table 4).
Discussion
START, a structured psychological intervention for 
family carers of people with dementia, improved carers’ 
depression and anxiety symptoms and quality of life not 
only in the short term, but also up to 24 months later. 
This is the ﬁ rst trial to show such results (panel 2).29 The 
magnitude of diﬀ erence in the total HADS symptoms is 
in the range that is important to patients and is clinically 
signiﬁ cant compared with other clinically meaningful 
changes.30 Similarly, the quality of life diﬀ erence between 
the START and TAU groups is the same magnitude as 
that between depressed and non-depressed community 
residents.17 At 2 year follow-up, carers in the control TAU 
group were seven times more likely to have clinically 
signiﬁ cant depression than in the START intervention 
group–this result is by deﬁ nition clinically signiﬁ cant. 
START is also cost eﬀ ective over both short and long 
term. Both community social care and care-home costs 
rose over time for the patients with dementia in both 
groups, as a result of worsening dementia. Care-home 
costs increased in both groups, with a greater increase in 
TAU than START, although this result was not 
signiﬁ cantly diﬀ erent. We are monitoring care-home 
admissions for another 5 years.
Previous successful interventions for aﬀ ective 
disorders in family carers show that coping strategies 
and individual (rather than group) therapy could be 
eﬀ ective for depressive symptoms, but little evidence 
exists for their eﬀ ect on anxiety. Previous studies have 
neither included prevention as an outcome, nor fully 
measured cost-eﬀ ectiveness; a review showed some 
evidence that interventions could generate savings,31 and 
a similar intervention to START showed a signiﬁ cant 
diﬀ erence in carer-time inputs over 6 months.32 Family 
carers become more anxious and depressed over time 
without an intervention; thus we did not exclude carers 
who were not depressed at the beginning of the study.33,34 
START’s preventive eﬀ ect underlines the fact that carers 
can beneﬁ t from early intervention.
A strength of our study was that carers were 
heterogeneous in sociodemographic and clinical 
characteristics, and recruited from varied services. Most 
patients had mild dementia at baseline, making the 
intervention generally acceptable to and applicable to 
family carers around the time UK patients present to 
secondary care with dementia. Limitations include the 
possibility of response bias in those who agreed to the 
study; because carer and patient morbidity levels were 
slightly higher than another cohort of newly referred 
people with dementia,35 those with more diﬃ  culties 
might have been more likely to consent to participate this 
trial. However, because the interventions in this study 
both prevented and treated depression, this therapy is 
likely to be applicable to those not in the investigation.36 
Panel 2: Research in context
Systematic Review
Before this study, we systematically reviewed evidence for family carer interventions 
for anxiety and depression using quality guidelines to prioritise high-quality evidence 
and combining it according to the type of intervention.2,30 We searched the electronic 
databases Allied and Complementary Medicine, British Nursing Index, CINAHL(R), 
Embase, Medline, the Cochrane systematic review database, and reference lists from 
articles, until June, 2005. We noted that interventions up to now had been delivered by 
highly trained clinicians, usually psychologists. The most eﬀ ective therapies were 
multicomponent, needed active participation of the carer, were tailored to individual 
carers, and delivered individually. They sometimes, over many years, delayed admission 
of people with dementia to a care home.
Interpretation
On the basis of our trial results we suggest that STrAtegies for RelaTives (START) is a 
clinical and cost-eﬀ ective intervention to treat and prevent depression and anxiety in 
family carers of people with dementia. This is the ﬁ rst time that these results have been 
shown to continue long-term (2 years). START is also cost-eﬀ ective for people with 
dementia, and these eﬀ ects also continue over 2 years. There is no other rigorous study 
of an intervention delivered by psychology graduates without previous clinical training, 
and no other extensive studies of cost-eﬀ ectiveness. Previous studies of similar 
interventions in the USA have shown results consistent with ours, but  our intervention 
might be more practical for many carers, because they did not need to all attend a group 
at the same time. Trials of psychosocial interventions in Europe (UK, Denmark, and 
Norway) using diﬀ erent models have been ineﬀ ective in terms of carers’ psychological 
symptoms and quality of life, thus showing that our results were not attributable solely 
to a therapist oﬀ ering time and attention. Future studies should assess the eﬀ ects of 
carer interventions on people with dementia in terms of clinical outcomes (ie, cognition 
and neuropsychiatric symptoms), and in the longer-term, care-home admission—we 
have extended our study for this latter aim. Additionally, we wish to further analyse the 
eﬀ ect of carer interventions on abuse, especially the interaction between abuse and care-
home admissions—abuse can lead to admission, and interventions for carers such as 
START could prevent further abuse and admissions. 
Figure 2: Cost-eﬀ ectiveness analysis for carer QALY gain
Cost-eﬀ ectiveness acceptability curve analysis done over 24 months. QALY=quality-adjusted life-year.
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The trial was not powered for the economic evaluation, 
which could account for the non-signiﬁ cance of those 
diﬀ erences. Follow-up showed a slight bias; adjustment 
for the bias suggested that START was slightly more cost 
eﬀ ective and clinically eﬀ ective than the primary analysis.
We minimised bias with standard measures validated 
for this population, independent randomisation, and 
follow-up assessors who were unaware of the allocation, 
although family carer participants inevitably knew the 
group allocation. At 2 years, the follow-up rate was 80% 
and sensitivity analyses showed similar results.
High ﬁ delity ratings and very low intercluster 
correlations indicate that the results do not diﬀ er between 
therapists, suggesting that START can be delivered 
consistently. START is multifaceted because these 
interventions are more likely to work in complex 
situations; qualitative follow-up substantiated our idea 
that carers used diﬀ erent components of the intervention.37 
However, therapists saw most people at their homes (153 
of 173) and were more ﬂ exible in timing than most NHS 
non-emergency services—eg, seeing 19 of 173 participants 
in the evenings. Our evidence for costs and cost-
eﬀ ectiveness for this method of delivery at home suggests 
that it should be feasible to provide in this format.
In conclusion, the START intervention is clinically 
eﬀ ective in the long term, improving carer mood and 
quality of life for 2 years. It does not raise costs, and it is 
cost eﬀ ective in terms of both carer and patient outcomes, 
with respect to NICE cost thresholds.
Many countries face rapidly growing numbers of 
people with dementia, including single people, over the 
coming decades, and policy frameworks assume their 
families will remain frontline providers of (unpaid) 
support. Most people with dementia also prefer to receive 
support from family members. In these circumstances, a 
cost-neutral intervention such as START, which 
substantially improves family carer mental health and 
quality of life whether or not they live with the person 
with dementia, should be made widely available.
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